3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia
Guglielmo Manenti, Tommaso Perretta, Antonello Calcagni, Donatella Ferrari, Colleen P Ryan, Federico Fraioli, Rosaria Meucci, Andrea Malizia, Valerio Iacovelli, Enrico Finazzi Agrò, Roberto Floris, Guglielmo Manenti, Tommaso Perretta, Antonello Calcagni, Donatella Ferrari, Colleen P Ryan, Federico Fraioli, Rosaria Meucci, Andrea Malizia, Valerio Iacovelli, Enrico Finazzi Agrò, Roberto Floris
Abstract
Background: Transperineal laser ablation (TPLA) of the prostate is a novel, mini-invasive option for men with lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). Our aim was to assess the impact of ultrasound-guided TPLA regarding urodynamic improvement and sexual function, monitoring clinical data, postprocedural complications and imaging findings at 3-T multiparametric magnetic resonance imaging.
Methods: Forty-four patients aged ≥ 50 affected with moderate to severe LUTS (International Prostate Symptoms score ≥ 12) due to benign prostatic obstruction and refractoriness, intolerance or poor compliance to medical therapies underwent US-guided TPLA between May 2018 and February 2020. Clinical measurements included PSA, uroflowmetry, sexual function assessment (using the International Index of Erectile Function and Male Sexual Health Questionnaire-Ejaculatory Dysfunction short form) and quality of life questionnaire. Adverse events were evaluated using the Clavien-Dindo scale. Volume changes were measured by MRI and automatic segmentation software during 1-year follow-up. Registration: NCT04044573 - May 5th, 2018, https://www.clinicaltrials.gov RESULTS: MRI assessed the changes over time with a 53% mean reduction of adenoma volume and 71% of the ablated area, associated with clinical and functional improvement and resolution of LUTS in all cases. Five of 44 patients (11.3%) had urinary blockage due to clots and required re-catheterisation for 2 weeks. The overall adverse event rate was 7%.
Conclusion: US-guided TPLA performed as a safe, manageable and effective treatment for LUTS. It could be considered an alternative effective mini-invasive procedure to standard treatments for BPH in the outpatient setting.
Keywords: Laser therapy; Lower urinary tract symptoms; Magnetic resonance imaging; Prostatic hyperplasia.
Conflict of interest statement
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
© 2021. The Author(s).
Figures
References
- Professionals S-O EAU Guidelines: management of non-neurogenic male LUTS. In: Uroweb. . Accessed 13 May 2021
- Chapple CR (2001) Lower urinary tract symptoms suggestive of benign prostatic obstruction--triumph: design and implementation. Eur Urol 39:31–36. 10.1159/000052565
- Serati M, Andersson K-E, Dmochowski R, et al (2019) Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptoms. Eur Urol 75:129–168. 10.1016/j.eururo.2018.09.029
- Huang S-W, Tsai C-Y, Tseng C-S, et al (2019) Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ l5919. 10.1136/bmj.l5919
- Stojanovic N, Ignjatovic I, Djenic N, Bogdanovic D (2015) Adverse effects of pharmacological therapy of benign prostatic hyperplasia on sexual function in men. Srp Arh Celok Lek 143:284–289. 10.2298/SARH1506284S
- Jakse G, Bouffioux C, Leval J, Janknegt RA. Benign prostatic hyperplasia: conservative and operative management. Berlin Heidelberg: Springer; 1992.
- Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2020. J Urol 204:799–804. 10.1097/JU.0000000000001298
- Reich O, Gratzke C, Bachmann A, et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180:246–249. 10.1016/j.juro.2008.03.058
- Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT (2007) Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol 52:510–516. 10.1016/j.eururo.2007.01.088
- Cai H-J, Fang J-H, Kong F-L, et al (2021) Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy. Acta Radiol:028418512110032. 10.1177/02841851211003289
- Frego N, Saita A, Casale P, et al (2021) Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World J Urol. 10.1007/s00345-021-03685-7
- Park KJ, Choi SH, Lee JS, Kim JK, Kim M (2020) Interreader agreement with Prostate Imaging Reporting and Data System version 2 for prostate cancer detection: a systematic review and meta-analysis. J Urol 204:661–670. 10.1097/JU.0000000000001200
- Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA (2002) The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 14:245–250. 10.1038/sj.ijir.3900859
- Rosen RC, Catania JA, Althof SE et al (2007) Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urology 69:805–809. 10.1016/j.urology.2007.02.036
- Chen G, Tan JT, Ng K, Iezzi A, Richardson J (2014) Mapping of Incontinence Quality of Life (I-QOL) scores to Assessment of Quality of Life 8D (AQoL-8D) utilities in patients with idiopathic overactive bladder. Health Qual Life Outcomes 12:133. 10.1186/s12955-014-0133-0
- Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. 10.1097/
- Delgado DA, Lambert BS, Boutris N et al (2018) Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J Am Acad Orthop Surg Glob Res Rev 2:e088. 10.5435/JAAOSGlobal-D-17-00088
- Melzack R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1:277–299. 10.1016/0304-3959(75)90044-5
- Liu R-Q, Liu J-B, Duan S et al (2020) Dynamic prostatic and laser-ablated lesion volume change after transperineal laser ablation in canine: preliminary observation and its clinical significance. Int J Hyperth 37:1260–1267. 10.1080/02656736.2020.1842517
- Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10:14–25
- Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94:738–744. 10.1111/j.1464-410X.2004.05022.x
- Omar MI, Lam TB, Alexander CE et al (2014) Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP): clinical effectiveness of bipolar vs monopolar TURP. BJU Int 113:24–35. 10.1111/bju.12281
- Meng F, Gao B, Fu Q et al (2006) Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. J Androl 28:259–261. 10.2164/jandrol.106.000372
- Westwood J, Geraghty R, Jones P, Rai BP, Somani BK (2018) Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol 10:327–333. 10.1177/1756287218793084
- Roehrborn C, Barkin J, Gange S et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. J Urol 24:8802–8813
- Braeckman J, Denis L (2017) Management of BPH then 2000 and now 2016 – from BPH to BPO. Asian J Urol 4:138–147. 10.1016/j.ajur.2017.02.002
- Frieben RW, Lin H-C, Hinh PP, Berardinelli F, Canfield SE, Wang R (2010) The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl 12:500–508. 10.1038/aja.2010.33
- Lin Y-T, Amouyal G, Thiounn N, et al (2016) Intra-vesical prostatic protrusion (IPP) can be reduced by prostatic artery embolization. Cardiovasc Intervent Radiol 39:690–695. 10.1007/s00270-015-1235-8
- Kovács A (2017) Prostataarterienembolisation (PAE): Technik und Ergebnisse. Radiologe 57:641–651. 10.1007/s00117-017-0248-5
- Malling B, Røder MA, Brasso K, Forman J, Taudorf M, Lönn L (2019) Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol 29:287–298. 10.1007/s00330-018-5564-2
- Pacella CM, Patelli G, Iapicca G, et al (2020) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis 23:356–363. 10.1038/s41391-019-0196-4
- Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM (2017) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Intervent Radiol 40:1440–1446. 10.1007/s00270-017-1662-9
- de Rienzo G, Lorusso A, Minafra P, et al (2020) Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol S0302283820306357:95–103. 10.1016/j.eururo.2020.08.018
- Sperling DS, Farbstein A, Farbstein S, Gentile JC (2019) Early functional outcomes following in-bore transrectal MR image-guided focal laser ablation for men with benign prostatic hyperplasia at one year. Acta Radiol 60:1367–1371. 10.1177/0284185119826541
Source: PubMed